Skip to main content
SpringerLink
Log in

Abatacept

  • Chapter
  • First Online:
Adverse Events with Biomedicines

  • 1224 Accesses

Abstract

Abatacept (Orencia®, Brystol-Meyers Squibb) is a soluble fusion protein binding to CD80 and CD86, thus blocking their interaction with CD28 receptor and the consequent costimulatory signal to activate T lymphocytes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Abatacept (Orencia®) BLA125118 Medical Review FDA, Dec 2005

    Google Scholar 

  2. Abatacept (Orencia®) WC500048938 Scientific Discussion EMEA, June 2007

    Google Scholar 

  3. Abatacept (Orencia®) WC500095025 Scientific Discussion EMEA, July 2010

    Google Scholar 

  4. Abatacept (Orencia®) Prescribing Information BMS, Dec 2011

    Google Scholar 

  5. Abatacept (Orencia®) WC500135471 CHMP Assessment Report EMEA, Nov 2012

    Google Scholar 

  6. Xu Z, Juan V, Ivanov A et al (2012) Affinity and cross-reactivity engeenering of CTLA4-Ig to modulate T cell costimulation. J Immunol 189:4470–4477

    Article  PubMed  CAS  Google Scholar 

  7. Herrero-Beaumont G, Martinez-Calatrava MJ, Castañeda S (2012) Mecanismo de acción de abatacept: concordancia con su perfil clinico. Reumatol Clin 8:78–83

    Google Scholar 

  8. Bonelli M, Ferner E, Göschl L et al (2013) Abatacept (CTLA4-Ig) treatment reduces the migratory capacity of monocytes in patients with rheumatoid arthritis. Arthritis Rheum. doi:10.1002/art.37787 (accepted article)

  9. Keystone EC, Kremer JM, Russell A et al (2012) Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study. Ann Rheum Dis 71:857–861

    Article  PubMed  CAS  Google Scholar 

  10. Schiff M, Pritchard C, Huffstutter JE et al (2009) The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis 68:1708–1714

    Article  PubMed  CAS  Google Scholar 

  11. Matsubara T, Yamana S, Tohma S et al (2012) Tolerability and efficacy of abatacept in Japanese patients with rheumatoid arthritis: a phase I study. Mod Rheumatol. doi:10.1007/s10165-012-0722-x

    Google Scholar 

  12. Kaine J, Gladstein G, Strusberg I et al (2012) Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (Phase IIIb ALLOW study). Ann Rheum Dis 71:38–44

    Article  PubMed  CAS  Google Scholar 

  13. Takeuchi T, Matsubara T, Nitobe T et al (2012) Phase II dose−response study of abatacept in Japanese patients with active rheumatoid arthritis with an inadequate response to methotrexate. Mod Rheumatol. doi:10.1007/s10165-012-0668-z

    Google Scholar 

  14. Westhovens R, Robles M, Ximenes AC et al (2009) Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 68:1870–1877

    Article  PubMed  CAS  Google Scholar 

  15. Emery P, Durez P, Dougados M et al (2010) Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis 69:510–516

    Article  PubMed  CAS  Google Scholar 

  16. Genovese MC, Schiff M, Luggen M et al (2012) Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy. J Rheumatol 39:1546–1554

    Article  PubMed  CAS  Google Scholar 

  17. Schiff M (2011) Abatacept treatment for rheumatoid arthritis. Rheumatology 50:437–449

    Article  PubMed  CAS  Google Scholar 

  18. Weinblatt ME, Schiff M, Valente R et al (2013) Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis. Findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum 65:28–38

    Article  PubMed  CAS  Google Scholar 

  19. Kim PS, Ho GY, Prete PE et al (2012) Safety and efficacy of abatacept in eight rheumatoid arthritis patients with chronic hepatitis B. Arthritis Care Res 64:1265–1268

    CAS  Google Scholar 

  20. Germanidis G, Hytiroglou P, Zakalka M (2012) Reactivation of occult hepatitis B virus infection, following treatment of refractory rheumatoid arthritis with abatacept. J Hepatol 56:1420–1429

    Article  PubMed  Google Scholar 

  21. Goldzweig O, Hashkes PJ (2011) Abatacept in the treatment of polyarticular JIA: development, clinical utility, and place in therapy. Drug Des Devel Ther 5:61–70

    PubMed  CAS  Google Scholar 

  22. Ruperto N, Lovell DJ, Quartier P et al (2010) Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum 62:1792–1802

    Article  PubMed  CAS  Google Scholar 

  23. Zulian F, Balzarin M, Falcini F et al (20120) Abatacept for severe anti-tumor necrosis factor α refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res 62:821−825

    Google Scholar 

  24. Merrill JT, Burgos-Vargas R, Westhovens R et al (2010) The efficacy and safety of abatacept in patients with non-life threatening manifestations of systemic lupus erythematosus. Arthr Rheum 62:3077–3087

    Article  CAS  Google Scholar 

  25. Sandborn WJ, Colombel J-F, Sands BE (2012) Abatacept for Crohn's disease and ulcerative colitis. Gastroenterology 143:62–69

    Article  PubMed  CAS  Google Scholar 

  26. Song I-H, Heldmann F, Rudwaleit M et al (2011) Treatment of active ankylosing spondylitis with abatacept: an open-label, 24 week pilot study. Ann Rheum Dis 70:1108–1110

    Article  PubMed  CAS  Google Scholar 

  27. Lepka FK, Farrenq V, Canouï-Poitrine F et al (2012) Lack of efficacy of abatacept in axial spondyloarthropathies refractory to tumor-necrosis-factor inhibition. Jt Bone Spine 79:47–50

    Article  Google Scholar 

  28. Mease P, Genovese MC, Gladstein G (2011) Abatacept in the treatment of patients with psoriatic arthritis. Results of a six-month, multicenter, randomized, double blind, placebo-controlled, phase II trial. Arthr Rheum 63:939–948

    Article  CAS  Google Scholar 

  29. Florent A, Albert C, Giacchero D et al (2010) Reactivation of cutaneous psoriasis during abatacept therapy for spondyloarthropathies. Jt Bone Spine 77:616–627

    Article  Google Scholar 

  30. Elhai M, Meunier M, Matucci-Cerinic M et al (2012) Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann Rheum Dis. doi:10.1136/annrheumdis-2012-202657

    Google Scholar 

  31. Orban T, Bundy B, Becker D et al (2011) Co-stimulation with abatacept in patients with recent-onset Type 1 diabetes: a randomized, double blind, placebo-controlled trial. Lancet 378:412–419

    Article  PubMed  CAS  Google Scholar 

  32. Pham T, Bachelez H, Berthelot JM et al (2012) Abatacept therapy and safety management. Jt Bone Spine 79(s1):3−84

    Google Scholar 

  33. Oieda-Uribe M, Afif N, Dahan E et al (2013) Exposure to abatacept or rituximab in the first trimester of pregnancy in three women with autoimmune diseases. Clin Rheunatol. doi:10.1007/s10067-012-2156-4

    Google Scholar 

  34. Molloy ES (2011) PML and rheumatology: the contribution of the disease and drugs. Cleveland Clin J Med 78:s28–s32

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Verona, Verona, Italy

    Giuseppe Tridente

Authors
  1. Giuseppe Tridente
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giuseppe Tridente .

1 Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (XLS 70 kb)

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Italia

About this chapter

Cite this chapter

Tridente, G. (2014). Abatacept. In: Adverse Events with Biomedicines. Springer, Milano. https://doi.org/10.1007/978-88-470-5313-7_41

Download citation

Publish with us

Policies and ethics

Search

Navigation